Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

An ex­per­i­men­tal pill from Servi­er Phar­ma­ceu­ti­cals showed po­ten­tial­ly prac­tice-chang­ing re­sults in a nar­row group of brain can­cer pa­tients, cut­ting the risk of their can­cers pro­gress­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.